RT @synovialjoints: IL17A/Fi BImekizumab BKZ to Wk 24 achieved reduction in ⦠total spinal pain (SP) ⦠nocturnal SP
Tweet Content
IL17A/Fi BImekizumab BKZ to Wk 24 achieved reduction in
◦ total spinal pain (SP)
◦ nocturnal SP
◦ morning stiffness (BASDAI)
◦ fatigue (FACIT-F)
Deodhar et al, BE MOBILE 1,2 Abst 0409 https://t.co/vpCrG2COuB#ACR22 @RheumNow
Links
Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis I… http://bit.ly/3UV8S9R
Show on Archive Page
On
Display in Search Results
On
PDQ
Off